scholarly journals Aqueous humour cytokine changes during a loading phase of intravitreal ranibizumab or dexamethasone implant in diabetic macular oedema

2019 ◽  
Vol 98 (4) ◽  
Author(s):  
Dominika Podkowinski ◽  
Eva Orlowski‐Wimmer ◽  
Gerhard Zlabinger ◽  
Andreas Pollreisz ◽  
Anna‐Sophie Mursch‐Edlmayr ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Aqueous Humour ◽  
Diabetic Macular Oedema ◽  
Dexamethasone Implant ◽  
Intravitreal Ranibizumab

Effect of intravitreal ranibizumab injection on aqueous humour cytokine levels in patients with diabetic macular oedema

2016 ◽  
Vol 95 (4) ◽  
pp. e340-e341 ◽  
Author(s):  
Tomoyasu Shiraya ◽  
Satoshi Kato ◽  
Fumiyuki Araki ◽  
Takashi Ueta
Keyword(s):  
Macular Oedema ◽  
Aqueous Humour ◽  
Diabetic Macular Oedema ◽  
Intravitreal Ranibizumab ◽  
Cytokine Levels

Recommendations for the management of diabetic macular oedema with intravitreal dexamethasone implant: A national Delphi consensus study

2021 ◽  
pp. 112067212110528
Author(s):  
Laurent Kodjikian ◽  
Stephanie Baillif ◽  
Aude Couturier ◽  
Catherine Creuzot-Garcher ◽  
Marie-Noelle Delyfer ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Daily Practice ◽  
Dexamethasone Implant ◽  
Consensus Approach ◽  
Delphi Consensus ◽  
First Line ◽  
Anti Vegf ◽  
Intravitreal Dexamethasone Implant ◽  
Intravitreal Dexamethasone

Purpose The intravitreal dexamethasone implant (DEX-I) is an alternative to anti-VEGF for the first-line treatment of diabetic macular oedema (DME). However, several questions remain regarding its routine use and its place in certain situations not always specified in current recommendations. A national consensus approach was, therefore, initiated by French retinal experts. Methods An iterative Delphi consensus approach was used. A steering committee (SC) of seven experts analysed data from the literature to formulate statements divided into five key areas of treatment. These statements were submitted to the independent and anonymous electronic vote of 87 French retina experts among whom 39 expressed their opinion and therefore constituted the voting panel. Results After two rounds of voting, 22 and 7 of 38 statements received a strong consensus and a good consensus, respectively. The consensus level was higher for statements regarding first-line indications and safety of DEX-I compared to those regarding efficacy assessment, reprocessing time or pathophysiological biomarkers. The panellists recommended the preferential use of DEX-I for patients with limited availability for multiple injections, those who needed to undergo cataract surgery or who had a recent cardiovascular history, and as a therapeutic alternative to anti-VEGF in patients with a history of vitrectomy, retinal serous detachment, hyper-reflective points or dry exudates in optical coherence tomography (OCT). However, some statements proposed by SC experts were not validated. Conclusion This study provides some key recommendations to clinicians treating diabetic macular oedema, which may be useful when using intravitreal dexamethasone implants in daily practice.

scholarly journals Long-term efficacy and duration of action of dexamethasone implant, in vitrectomised and non-vitrectomised eyes with persistent diabetic macular oedema

Eye ◽  
2018 ◽  
Vol 33 (3) ◽  
pp. 411-418 ◽  
Author(s):  
George G. Bastakis ◽  
Dimitris Dimopoulos ◽  
Anastasios Stavrakakis ◽  
George Pappas
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Dexamethasone Implant ◽  
Duration Of Action ◽  
Term Efficacy

scholarly journals Real Life Experience of Dexamethasone Implant in Refractory Diabetic Macular Oedema

2019 ◽  
Vol Volume 13 ◽  
pp. 2583-2590
Author(s):  
Tommi Karttunen ◽  
Lasse Nummelin ◽  
Kai Kaarniranta ◽  
Kati Kinnunen
Keyword(s):  
Macular Oedema ◽  
Life Experience ◽  
Real Life ◽  
Diabetic Macular Oedema ◽  
Dexamethasone Implant

Disorganization of retinal inner layers as a biomarker in patients with diabetic macular oedema treated with dexamethasone implant

2019 ◽  
Vol 98 (2) ◽  
Author(s):  
Dinah Zur ◽  
Matias Iglicki ◽  
Anna Sala‐Puigdollers ◽  
Jay Chhablani ◽  
Marco Lupidi ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Dexamethasone Implant

scholarly journals Dexamethasone implant for the treatment of persistent diabetic macular oedema despite long‐term treatment with bevacizumab

2018 ◽  
Vol 47 (2) ◽  
pp. 287-289 ◽  
Author(s):  
Aaron W. Joe ◽  
Sanjeewa S. Wickremasinghe ◽  
Mark C. Gillies ◽  
Vuong Nguyen ◽  
Lyndell L. Lim ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Term Treatment ◽  
Dexamethasone Implant ◽  
Long Term Treatment

Differences in cysts characteristics and related influence on the anatomical response after dexamethasone implant in diabetic macular oedema

Eye ◽  
2021 ◽  
Author(s):  
Mariacristina Parravano ◽  
Serena Fragiotta ◽  
Eliana Costanzo ◽  
Daniela Giannini ◽  
Daniele De Geronimo ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Dexamethasone Implant

Micro‐ RNAs in the aqueous humour of patients with diabetic macular oedema

2020 ◽  
Vol 48 (5) ◽  
pp. 624-635
Author(s):  
Heeyoon Cho ◽  
Mina Hwang ◽  
Eun H. Hong ◽  
Hyoseon Yu ◽  
Hyun‐Hee Park ◽  
...  
Keyword(s):  
Macular Oedema ◽  
Aqueous Humour ◽  
Diabetic Macular Oedema ◽  
Micro Rnas
Sign in / Sign up

Export Citation Format

Share Document